融合-话题@MedSci

#融合#

253篇内容 | 1724人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1525574, encodeId=73ca15255e4a7, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=IEEE trans:基于运动协同分析和多模态融合的脑卒中后康复上肢运动功能定量评估, objectType=article, longId=213265, objectId=990e213265da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=990e213265da, replyNumber=0, likeNumber=33, createdTime=2021-06-27, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=990e213265da, moduleTitle=IEEE trans:基于运动协同分析和多模态融合的脑卒中后康复上肢运动功能定量评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=990e213265da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525573, encodeId=f88c15255e374, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=IEEE trans:基于生物融合的上肢虚拟康复系统：虚拟现实对肌肉疲劳感、游戏性能和用户体验的影响, objectType=article, longId=212711, objectId=3eee212e11dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eee212e11dd, replyNumber=0, likeNumber=27, createdTime=2021-06-15, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eee212e11dd, moduleTitle=IEEE trans:基于生物融合的上肢虚拟康复系统：虚拟现实对肌肉疲劳感、游戏性能和用户体验的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eee212e11dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525572, encodeId=f72215255e2f6, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC, objectType=article, longId=212697, objectId=084e21269e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=084e21269e30, replyNumber=0, likeNumber=36, createdTime=2021-06-15, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=084e21269e30, moduleTitle=Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=084e21269e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525571, encodeId=b31215255e11d, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性, objectType=article, longId=212443, objectId=a7a32124431f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7a32124431f, replyNumber=0, likeNumber=29, createdTime=2021-06-09, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7a32124431f, moduleTitle=JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7a32124431f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525570, encodeId=20c215255e0d2, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle= ASCO 2021：摘要概览与展望21 | zenocutuzumab治疗晚期胰腺癌、NRG1融合实体肿瘤的有效性和安全性, objectType=article, longId=212300, objectId=666a21230082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=666a21230082, replyNumber=0, likeNumber=41, createdTime=2021-06-06, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=666a21230082, moduleTitle= ASCO 2021：摘要概览与展望21 | zenocutuzumab治疗晚期胰腺癌、NRG1融合实体肿瘤的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=666a21230082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525569, encodeId=9712152556983, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=室性融合波的判别？, objectType=article, longId=211762, objectId=8f5a211e62f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5a211e62f3, replyNumber=0, likeNumber=0, createdTime=2021-05-26, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5a211e62f3, moduleTitle=室性融合波的判别？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f5a211e62f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525568, encodeId=49cc15255685c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=中国NMPA接受PD-1 /TGF-β双功能融合蛋白临床试验的申请, objectType=article, longId=208187, objectId=c0e920818eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e920818eda, replyNumber=0, likeNumber=32, createdTime=2021-03-10, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e920818eda, moduleTitle=中国NMPA接受PD-1 /TGF-β双功能融合蛋白临床试验的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e920818eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525567, encodeId=58f3152556e7e, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=28, createdTime=2021-03-04, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525566, encodeId=92651525566bb, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, objectType=article, longId=206525, objectId=468b20652504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468b20652504, replyNumber=0, likeNumber=31, createdTime=2021-02-02, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468b20652504, moduleTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468b20652504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525565, encodeId=62f315255653a, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, objectType=article, longId=205799, objectId=475b205e990c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475b205e990c, replyNumber=0, likeNumber=34, createdTime=2021-01-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475b205e990c, moduleTitle=JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475b205e990c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Scand J Urol：前列腺癌术后的融合靶向活检Gleason评分变化 , objectType=article, longId=205541, objectId=4dad20554148, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad20554148, replyNumber=0, likeNumber=43, createdTime=2021-01-11, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad20554148, moduleTitle=Scand J Urol：前列腺癌术后的融合靶向活检Gleason评分变化 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dad20554148)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525563, encodeId=fa4715255632b, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , objectType=article, longId=205518, objectId=dfc82055184d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc82055184d, replyNumber=0, likeNumber=49, createdTime=2021-01-10, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc82055184d, moduleTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc82055184d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525562, encodeId=275615255628c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=百度智慧医疗用AI助力国家基层糖尿病医防融合服务模式探索, objectType=article, longId=204154, objectId=f72f204154f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72f204154f9, replyNumber=0, likeNumber=34, createdTime=2020-12-07, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72f204154f9, moduleTitle=百度智慧医疗用AI助力国家基层糖尿病医防融合服务模式探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72f204154f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525561, encodeId=2976152556199, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征, objectType=article, longId=203961, objectId=21bc20396187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21bc20396187, replyNumber=0, likeNumber=0, createdTime=2020-12-02, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21bc20396187, moduleTitle=ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21bc20396187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525560, encodeId=e10715255605d, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Acta Neuropathologica: 幕下C11orf95融合胶质瘤与幕上RELA融合室管膜瘤共有组织学、免疫表型和分子特征, objectType=article, longId=203734, objectId=cb67203e3425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb67203e3425, replyNumber=0, likeNumber=24, createdTime=2020-11-27, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb67203e3425, moduleTitle=Acta Neuropathologica: 幕下C11orf95融合胶质瘤与幕上RELA融合室管膜瘤共有组织学、免疫表型和分子特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb67203e3425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525559, encodeId=410c152555945, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移, objectType=article, longId=203657, objectId=d34920365e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d34920365e0b, replyNumber=0, likeNumber=36, createdTime=2020-11-24, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d34920365e0b, moduleTitle=Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d34920365e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525558, encodeId=ec6615255584c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, objectType=article, longId=203466, objectId=48e120346625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e120346625, replyNumber=0, likeNumber=37, createdTime=2020-11-18, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e120346625, moduleTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48e120346625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525557, encodeId=5f9f152555e83, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, objectType=article, longId=202449, objectId=39aa20244938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39aa20244938, replyNumber=0, likeNumber=35, createdTime=2020-10-26, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39aa20244938, moduleTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39aa20244938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Sci Rep：NONO-TFE3双融合FISH检测作为NONO-TFE3肾细胞癌诊断工具的适用性, objectType=article, longId=202264, objectId=bab220226493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bab220226493, replyNumber=0, likeNumber=42, createdTime=2020-10-20, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bab220226493, moduleTitle=Sci Rep：NONO-TFE3双融合FISH检测作为NONO-TFE3肾细胞癌诊断工具的适用性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bab220226493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525555, encodeId=7e34152555555, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=北京、长三角专家微医对话推动医疗健康服务全要素数字化融合, objectType=article, longId=201747, objectId=7a73201e472e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a73201e472e, replyNumber=0, likeNumber=48, createdTime=2020-10-07, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a73201e472e, moduleTitle=北京、长三角专家微医对话推动医疗健康服务全要素数字化融合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a73201e472e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

融合

2020-05-29

licz0427 (审核中...)

前往app查看评论内容

#融合#

IEEE trans:基于运动协同分析和多模态融合的脑卒中后康复上肢运动功能定量评估

2021-06-27

licz0427 (审核中...)

前往app查看评论内容

#融合#

IEEE trans:基于生物融合的上肢虚拟康复系统：虚拟现实对肌肉疲劳感、游戏性能和用户体验的影响

2021-06-15

licz0427 (审核中...)

前往app查看评论内容

#融合#

Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC

2021-06-15

licz0427 (审核中...)

前往app查看评论内容

#融合#

JCO：NRG1融合阳性肺癌的临床病理特征和对各种治疗的反应性

2021-06-09

licz0427 (审核中...)

前往app查看评论内容

#融合#

ASCO 2021：摘要概览与展望21 | zenocutuzumab治疗晚期胰腺癌、NRG1融合实体肿瘤的有效性和安全性

2021-06-06

licz0427 (审核中...)

前往app查看评论内容

#融合#

室性融合波的判别？

2021-05-26

licz0427 (审核中...)

前往app查看评论内容

#融合#

中国NMPA接受PD-1 /TGF-β双功能融合蛋白临床试验的申请

2021-03-10

licz0427 (审核中...)

前往app查看评论内容

#融合#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-03-04

licz0427 (审核中...)

前往app查看评论内容

#融合#

Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价

2021-02-02

licz0427 (审核中...)

前往app查看评论内容

#融合#

JCO Precision Oncol：NTRK融合在儿童肿瘤中比预期的更常见

2021-01-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

Scand J Urol：前列腺癌术后的融合靶向活检Gleason评分变化

2021-01-11

licz0427 (审核中...)

前往app查看评论内容

#融合#

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

2021-01-10

licz0427 (审核中...)

前往app查看评论内容

#融合#

百度智慧医疗用AI助力国家基层糖尿病医防融合服务模式探索

2020-12-07

licz0427 (审核中...)

前往app查看评论内容

#融合#

ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征

2020-12-02

licz0427 (审核中...)

前往app查看评论内容

#融合#

Acta Neuropathologica: 幕下C11orf95融合胶质瘤与幕上RELA融合室管膜瘤共有组织学、免疫表型和分子特征

2020-11-27

licz0427 (审核中...)

前往app查看评论内容

#融合#

Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移

2020-11-24

licz0427 (审核中...)

前往app查看评论内容

#融合#

非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效

2020-11-18

licz0427 (审核中...)

前往app查看评论内容

#融合#

FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者

2020-10-26

licz0427 (审核中...)

前往app查看评论内容

#融合#

Sci Rep：NONO-TFE3双融合FISH检测作为NONO-TFE3肾细胞癌诊断工具的适用性

2020-10-20

licz0427 (审核中...)

前往app查看评论内容

#融合#

北京、长三角专家微医对话推动医疗健康服务全要素数字化融合

2020-10-07

科室
- - 订阅+
  - 更多科室
工具
服务